by Pill Pals | Mar 12, 2025 | News
Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.K....
by Pill Pals | Mar 12, 2025 | News
Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Virology Department, AP-HP, Hôpital Saint-Louis, Paris, France (M....
by Pill Pals | Mar 12, 2025 | News
ListenWelcome to the FDA Drug Safety Podcast for health care professionals from the Division of Drug Information.Based on its review of postmarket clinical trial data, on December 12, 2024, the FDA announced identified cases of serious liver injury among patients...
by Pill Pals | Mar 12, 2025 | News
Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Institut Pasteur, Paris, France (C. Savin, J. Pizarro-Cerdá); Instituto...
by Pill Pals | Mar 12, 2025 | News
Update | February 7, 2025The Drug Development Tool (DDT) Qualification Programs and ISTAND1 Pilot Program, have updated the program metrics to give the public and industry partners more clarity and transparency around our activities. In accordance with the 21st...
by Pill Pals | Mar 12, 2025 | News
Delivery Method: VIA UPS Product: Drugs Recipient: Recipient Name Mr. Seunghyun Cho Recipient Title General Manager Natuzen Co., Ltd. 289 Namdongdong-RoNamdong-guIncheon21639South Korea Issuing Office: Center for Drug Evaluation and Research | CDER United States...